Viable dual therapy second-line antiretroviral regimen for Africa?

Affiliations

Comment

Paula Munderi. Lancet HIV. 2017 Sep.

. 2017 Sep;4(9):e376-e377.

doi: 10.1016/S2352-3018(17)30090-5. Epub 2017 May 28.

¹ MRC/UVRI Uganda Research Unit on AIDS, Uganda Virus Research Institute, PO Box 49, Entebbe, Uganda.

No abstract available

Comment on

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, Ayangma L, Zoungrana J, Gueye NFN, Diallo M, Izard S, Bado G, Kane CT, Aghokeng AF, Peeters M, Girard PM, Le Moing V, Reynes J, Delaporte E; MOBIDIP study group. Ciaffi L, et al. Lancet HIV. 2017 Sep;4(9):e384-e392. doi: 10.1016/S2352-3018(17)30069-3. Epub 2017 May 28. Lancet HIV. 2017. PMID: 28566227 Clinical Trial.